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Transcriptional profiling of HERV-K(HML-2)
in amyotrophic lateral sclerosis and
potential implications for expression of
HML-2 proteins
Jens Mayer1* , Christian Harz1, Laura Sanchez2, Gavin C. Pereira3, Esther Maldener1, Sara R. Heras2,7,
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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder. About 90% of ALS cases are
without a known genetic cause. The human endogenous retrovirus multi-copy HERV-K(HML-2) group was recently
reported to potentially contribute to neurodegeneration and disease pathogenesis in ALS because of transcriptional
upregulation and toxic effects of HML-2 Envelope (Env) protein. Env and other proteins are encoded by some
transcriptionally active HML-2 loci. However, more detailed information is required regarding which HML-2 loci are
transcribed in ALS, which of their proteins are expressed, and differences between the disease and non-disease
states.
Methods: For brain and spinal cord tissue samples from ALS patients and controls, we identified transcribed HML-2
loci by generating and mapping HML-2-specific cDNA sequences. We predicted expression of HML-2 env gene-
derived proteins based on the observed cDNA sequences. Furthermore, we determined overall HML-2 transcript
levels by RT-qPCR and investigated presence of HML-2 Env protein in ALS and control tissue samples by Western
blotting.
Results: We identified 24 different transcribed HML-2 loci. Some of those loci are transcribed at relatively high
levels. However, significant differences in HML-2 loci transcriptional activities were not seen when comparing ALS
and controls. Likewise, overall HML-2 transcript levels, as determined by RT-qPCR, were not significantly different
between ALS and controls. Indeed, we were unable to detect full-length HML-2 Env protein in ALS and control
tissue samples despite reasonable sensitivity. Rather our analyses suggest that a number of HML-2 protein variants
other than full-length Env may potentially be expressed in ALS patients.
Conclusions: Our results expand and refine recent publications on HERV-K(HML-2) and ALS. Some of our results are
in conflict with recent findings and call for further specific analyses. Our profiling of HML-2 transcription in ALS
opens up the possibility that HML-2 proteins other than canonical full-length Env may have to be considered when
studying the role of HML-2 in ALS disease.
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Background
Amyotrophic lateral sclerosis (ALS) is a late-onset fatal
neurodegenerative disorder affecting motor neurons and
with an incidence of about 2 in 100,000. In the United
States of America, approximately 5600 people are diag-
nosed with ALS each year with an average life expectancy
of about two to 5 years from time of diagnosis. The dis-
ease is variable, however, and many people live longer.
About 90% of ALS cases are sporadic (sALS), the majority
with unknown genetic cause, while the remaining cases
are familial (fALS). To date at least 25 genes have been
linked to ALS [1, 2]. The first ALS gene discovered, super-
oxide dismutase (SOD1) [3], is mutated in about 20% of
fALS and up to 4% of sALS cases. C9orf72 is by far the
most frequent gene, accounting for about 35% of fALS
and 6% of sALS cases [4]. FUS RNA binding protein
(FUS) and TAR DNA binding protein (TDP-43 or
TARDBP) genes each account for about 4% of fALS cases,
but other ALS-associated genes are found in less than 2%
of fALS patients. Among the many factors implicated in
the development of ALS are certain classes of transposable
elements (TEs). TEs include long terminal repeat (LTR)
and non-LTR class retrotransposons that move by a “copy
and paste” mechanism involving reverse transcription of
their RNA and insertion of the cDNA copy at a new gen-
omic location. Among the LTR-retrotransposons, human
endogenous retroviruses (HERVs) are remnants of infec-
tions by exogenous retroviruses that formed proviruses in
the germ line that became inheritable.
Approximately 8% of the human genome mass is directly
or indirectly derived from retroviral sequences. HERV se-
quences are usually several millions of years old and have
lost gene-coding competence due to accumulation of non-
sense mutations. Although they tend to be transcriptionally
repressed, HERV transcripts can be found in many human
tissue and cell types, and deregulated transcription of
HERV sequences has been reported for a number of hu-
man diseases (for reviews, see [5–8]).
The HERV-K(HML-2) group comprises a number of
evolutionarily young proviruses, some of which are
human-specific or even polymorphic in the human
population, suggesting recent insertional activity [9–11].
Several HERV-K(HML-2) (henceforth abbreviated as
HML-2) proviruses still encode retroviral proteins or
modified derivatives caused by mutations. Some
HML-2-encoded proteins, especially those derived from
the HML-2 env gene region, have been reported to im-
pact cellular physiology (reviewed in [12, 13]).
There are two different HML-2 provirus types in the
human genome that differ by a 292-bp indel sequence in
the env gene 5′ region; HML-2 type 1 proviruses lack
these 292 bp, while type 2 proviruses contain them
(Fig. 1). Type 1 and type 2 proviruses undergo different
secondary splicing following initial splicing of env
mRNA from full-length proviral transcripts. Type 2 pro-
viruses harbor a splice donor (SD) site located within
the 292-bp sequence that, in combination with a splice
acceptor (SA) just upstream of the proviral 3′ LTR, gen-
erates the rec transcript lacking most of the (intronic)
env gene. Type 1 proviruses display an alternative spli-
cing pattern, generating the np9 transcript by utilizing
another SD site that evolved relatively late during pri-
mate evolution [14, 15]. Various HML-2 loci in the hu-
man genome possess coding capacity for Rec or Np9
protein [16, 17].
Misregulation of HERV-K(HML-2) transcription has
been implicated in the etiology of a number of disease
conditions, most notably cancers. HML-2 Rec protein was
reported to interact with a number of cellular proteins,
specifically promyelocytic zinc finger protein (PLZF), tes-
ticular zinc finger protein (TZFP), Staufen-1, and human
small glutamine-rich tetratricopeptide repeat containing
(hSGT), the latter potentially enhancing activity of the an-
drogen receptor. HML-2 Rec may furthermore interfere
with germ cell tumor (GCT) development and may dir-
ectly contribute to tumorigenesis, as it is known to disturb
Fig. 1 Depiction of a canonical HERV-K(HML-2) type 2 provirus and RT-PCR amplicons. Proviral 5′ and 3′ Long Terminal Repeats (LTR), gag, pro, pol
and env genes, splice donor (SD) and splice acceptor (SA) sites, splicing patterns of full-length (f-l) proviral transcripts, and three different RT-PCR
amplicons for identification of transcribed HML-2 loci within the gag and the env gene regions (gag amplicon, env600nt amplicon) are indicated,
with the rec/np9 amplicon spanning an intron within env. Location of PCR primers for amplifcation of rec/np9 transcripts are indicated by arrows.
A 292-bp deletion in the env gene 5′ region distinguishes HML-2 type 1 from type 2 proviruses and causes an alternative splicing pattern
generating the np9 transcript. Env-SP consisting of the N-terminal 96 aa of full-length Env protein is indicated (see also Fig. 4)
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germ cell development in mice and change testis histology
towards a carcinoma-like phenotype [18–24]. HML-2 Rec
was also reported to directly bind to approximately 1600
different cellular RNAs and to modulate their ribosome
occupancy with unknown cellular consequences [25].
HML-2 Np9 protein was reported to also interact with
PLZF and with the ligand of Numb protein X (LNX),
suggesting a possible role of Np9 in tumorigenesis in-
volving the LNX/Numb/Notch pathway [18, 20]. Np9
protein was furthermore reported to activate ERK, AKT
and Notch1 pathways, to upregulate β-catenin, to inhibit
or promote growth of leukemic cells according to its re-
pression or overexpression, and to display elevated pro-
tein levels in leukemia patients [26]. HML-2 Rec and
Np9 protein expression has also been demonstrated in
different disease contexts, among them GCT, melanoma
[27], and in synovia from rheumatoid arthritis [28].
There are recent reports of additional HML-2 protein
variants that are due to alternative splicing of the
HML-2 env gene region or to variant proviruses that po-
tentially generate chimeric HML-2 Env/Rec/Np9 pro-
teins [17, 29, 30]. However, expression of such proteins
in vivo and their potential functions remain to be
studied.
HML-2 Env protein expression has also been observed
in different human tumor types, among them GCT and
melanoma (reviewed in ref. [12]). HML-2 Env appears to
have tumorigenic potential. Lemaître et al. [31] reported
epithelial to mesenchymal transition following HML-2
Env expression and induction of different transcription
factors that affect the MAPK/ERK pathway that is asso-
ciated with cellular transformation processes. Of note,
the cytoplasmic tail of the transmembrane (TM) domain
of HML-2 Env appears to play an important role in that
context [31]. Reduction of HML-2 env transcripts by
siRNA was reported to reduce tumorigenic potential of
a melanoma cell line [32]. A role for HML-2 Env in
tumorigenesis and metastasis of breast cancer cells was
also reported [33]. Finally, an immunosuppressive do-
main within the HML-2 Env-TM region inhibited prolif-
eration of human immune cells, modulated expression
of cytokines, and altered expression of other cellular
genes [34].
While HML-2 type 2 provirus-encoded Env protein is
regarded as the canonical HML-2 Env protein, it was re-
cently established that some HML-2 type 1 proviruses
encode an Env-like protein that lacks N-terminal re-
gions, but includes outer membrane (OM) and TM re-
gions and that such HML-2 type 1-encoded Env can
undergo post-translational processing [35]. It was fur-
thermore shown that canonical HML-2 type 2 Env en-
codes a ca. 13 kDa signal peptide, named HML-2 SP,
that does not enter the usual degradation pathway but is
stable and displays protein function different from
HML-2 Rec protein with which it shares a long sequence
portion. Because of similarities with the Mouse
Mammary Tumor Virus encoded p14/SPRem protein, it
is conceivable that HML-2 SP likewise interacts with
nucleophosmin (NPM1 or B23) and thus may interfere
with important cellular processes [36].
In addition to cancer, HERV involvement in several
neurological and neuropsychiatric conditions has been
proposed, including multiple sclerosis, schizophrenia,
and HIV-associated dementia (reviewed in ref. [37]).
HERV-K(HML-2) has also been implicated in ALS. In-
creased reverse transcriptase activity from an unknown
source is detectable in sera and cerebro-spinal fluids of
non-HIV-infected sALS patients [38–41]. In one study,
an increase in HERV-K pol transcripts deriving from
several HML-2 and HML-3 loci was reported in brain
tissues of ALS patients but not in Parkinson’s patients or
accidental death controls [42]. It should be noted, how-
ever, that HERV-K(HML-3) is unlikely to encode an ac-
tive RT due to the overall mutational load of HML-3
sequences [43]. Also co-amplified HML-3 transcripts
may have contributed to measurements of overall
HML-2 transcript levels in RT-qPCR experiments of that
study.
Mutations in the TDP-43 gene cause a dominant form
of ALS and are involved in about 4% of fALS and 1% of
sALS patients. TDP-43 protein aggregation has emerged
as a unifying pathological marker of a majority of ALS
and frontotemporal lobar degeneration (FTLD) cases
[44]. Correlation of TDP-43 and HERV-K(HML-2) RT
and pol expression in brain tissues has been reported
[42, 45], although that link is controversial. Although Li
et al. [46] reported TDP-43 protein bound the HERV-K
LTR with an attendant increase in HERV-K transcription
and RT activity, Manghera et al. [47] found that
wild-type TDP-43 binds the HML-2 LTR without alter-
ing transcription, while mutant TDP-43 promotes
HML-2 RT protein aggregation resulting in its clearance
from astrocytes but not neurons. A recent study by Pru-
dencio et al. [48] found no association between TDP-43
expression in frontal cortex samples or phosphorylated
TDP-43 protein levels in FTLD or ALS/FTLD patients
and repetitive element expression.
Recently, a number of experiments have implicated
HML-2 Env protein as contributing to ALS neurode-
generation. HML-2 Env was reported to be expressed
in cortical and spinal neurons of ALS patients, and
Env expression affected neurites phenotypically, while
mice transgenic for HML-2 env showed progressive
motor dysfunction accompanied by other ALS-typical
anomalies [46]. In sum, while some HERV-K
(HML-2)-derived products have been implicated in
ALS, their contribution to disease has not been
definitively proven.
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Transcriptional activity of HERV-K(HML-2) has
been studied by different approaches (for instance, see
[30, 49–54]). HML-2 transcripts can be identified in a
number of tissue and cell types (see above), and there
have been various attempts to identify the actual
transcribed HML-2 loci contributing to the HML-2
“transcriptome”. Identification of transcribed HML-2
loci provides crucial information as to (i) the source
of deregulated transcription of HML-2 loci when
comparing diseased and controls, (ii) the actual pro-
tein coding-capacity of transcribed HML-2 loci of
possible relevance for a specific disease, and (iii)
potentially variant HML-2 proteins that should be
considered when studying disease relevance.
To identify transcribed HML-2 loci, we and others
have employed a strategy involving generation of
HML-2 cDNAs, followed by their PCR-amplification,
cloning of PCR products, Sanger DNA sequencing and
assignment of these sequences to known HML-2 loci by
means of pairwise sequence comparisons to identify the
HML-2 loci most likely to have generated the original
transcripts. Transcribed HML-2 loci have been identified
in various tissue and cell types, including GCT, prostate
cancer, brain, ALS, melanoma, and embryonic and pluri-
potent stem cells [29, 30, 42, 50, 55, 56]. It can be con-
cluded from such studies that tissue and cell types
display quite different transcription profiles of specific
HML-2 proviruses.
An alternative approach for identification of tran-
scribed HML-2 loci involves assignment of HML-2
cDNA sequences that were generated by next generation
sequencing, that is, RNA-Seq. For instance, two studies
[25, 49] used RNA-sequencing to identify transcribed
HML-2 loci in the teratocarcinoma cell line Tera-1 and
human blastocysts, respectively. However, such an ap-
proach typically generates short sequence reads and so
tends to be problematic when cDNA sequences need to
be assigned unambiguously to HML-2 loci that are very
similar in sequence [49]. This is especially true when
assigning RNA-Seq reads to evolutionarily younger,
protein-coding-competent HML-2 loci. Furthermore,
RNA-Seq can produce biased results because of the rela-
tively low number of reads deriving from HERVs tran-
scribed from their own promoters, compared to
RNA-Seq reads from HERV sequences contained within
longer gene promoter-driven mRNA transcripts. Quality
long sequence reads, as generated by Sanger-based se-
quencing, currently appear superior for a more unbiased
identification of transcribed HML-2 loci.
Precise knowledge of HML-2 loci transcribed in ALS
and normal controls allows conclusions concerning
HML-2 proteins potentially expressed in ALS and po-
tentially exerting biological functions. To expand upon
previously published reports linking HERV-K(HML-2)
with ALS, in the present study we applied our recently
optimized strategy [17, 30] for identification of tran-
scribed HML-2 loci to profile transcription of HML-2
loci in various tissue samples from mostly sALS or ALS
of unknown etiology and control individuals using three
different RT-PCR amplicons within the HML-2 proviral
sequence. We examined the protein coding capacity of
transcribed HML-2 loci with special emphasis on pro-
teins encoded by the HML-2 env gene region. We fur-
thermore examined HML-2 transcript levels by
RT-qPCR and expression of HML-2 env gene-derived
proteins in ALS and control tissue samples by Western
blotting. We also assayed by RT-qPCR transcript levels
of the HERV-W group that has been linked with other
neurological diseases, including schizophrenia and mul-
tiple sclerosis [37]. Overall, our study did not detect
compelling differences in transcription of HML-2 loci in
ALS versus control samples. It does, however, provide
potentially useful information for further studies on the
relevance of HML-2 transcription in ALS, the role of
HML-2 encoded proteins in the ALS context, and
HML-2 proteins and variants to be considered in future
studies.
Methods
RNA extraction from tissue samples and cDNA generation
for RT-qPCR
Post-mortem brain and spinal cord frozen tissues were ob-
tained from the University of Maryland Brain and Tissue
Bank of the NIH Neurobiobank, The Target ALS Multicen-
ter Postmortem Tissue Core of Johns Hopkins University
School of Medicine, and the Department of Neurosciences
of the University of California San Diego School of
Medicine. Human 2102Ep embryonal carcinoma cells (a
gift from P.K. Andrews, University of Sheffield) and human
embryonic fibroblasts (HEFs, ATCC) were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% FBS and Pen-Strep. H9 (WA09) human
Embryonic Stem Cells (hESCs) [57] were obtained from
Wicell (RRID: CVCL_9773) and cultured and passaged as
previously described [58].
For RNA extractions for RT-qPCR, all brain tissue and
some spinal cord tissues were disrupted and homoge-
nized in 500 μl of Trizol (Invitrogen) using the TissueLy-
ser LT (Qiagen). Briefly, 30 mg of sample were
transferred to a 2 ml tube containing 250 μl of Trizol
and one 5 mm stainless steel bead. The TissueLyser LT
program used was 50 Hz for 1 min. After a spin, the
supernatant was collected and another 250 μl were
added to the sample to repeat the same procedure.
Finally, we combined both fractions and proceeded with
RNA purification following the Trizol manufacturer’s in-
structions. Some spinal cord samples were homogenized
in 500 μl of Trizol and 5 zirconium silicate beads using
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a Benchmark BeadBlaster 24. Following centrifugation,
the supernatant was further purified using RNeasy Mini
Kit with On-column DNase digestion with the
RNase-Free DNase Set (Qiagen).
Next, the RNA was treated with RQ1 RNase-free
DNase (Promega) for 30 min, purified with ultrapure
phenol:chloroform:isoamyl alcohol mixed at 25:24:1
[v/v/v] (Ambion) and precipitated with 3 vol. ice cold
100% ethanol and 0.1 vol. 3 M sodium acetate
pH 5.2. Some spinal cord tissues used for RT-qPCR
were homogenized in 500 μl of Trizol and zirconium
silicate beads using a Benchmark BeadBlaster 24.
Following centrifugation, the supernatant was further
purified using an RNeasy Mini Kit with On-column
DNase digestion (Qiagen). To assure absence of
cross-contaminating genomic DNA, 1 μg of total
RNA from all samples was treated again with another
round of RNase-free DNase I (Invitrogen) for
15 min.
A high-capacity cDNA Reverse Transcription kit
(Applied Biosystems) was used to generate cDNA.
We included an internal control (no RT added) that
was run in all qPCRs (see below).
RNA integrity numbers (RINs) were determined using
an Agilent BioAnalyzer and an Agilent RNA 6000 Nano
Kit following the manufacturer’s recommendations.
Mean RIN was 6.3 (SD = 2.1; 71% with RIN > 5)
(Additional file 1: Table S1, Additional file 2: Figure S9).
We attribute lower RIN numbers in some samples to
long post-mortem intervals affecting tissue quality, two
necessary cycles of freezing-thawing of the RNAs, and
rigorous DNase-treatments of RNA that were required
to remove residual contaminating genomic DNA, a
strategy necessary for our sensitive PCR amplification of
multi-copy repeat cDNAs lacking introns.
RT-PCR of HERV-K(HML-2) transcripts
We generated cDNA following previously established
procedures [17, 30]. Briefly, we treated approximately
5.5 μg of total RNA with DNase in a total volume of
55 μl using TURBO DNA-free Kit (Ambion/Life Tech-
nologies) following the protocol for rigorous DNase
treatment. We synthesized cDNA from DNase-treated
total RNA (final concentration ~ 40 ng/μl) using Omnis-
cript RT Kit (Qiagen) and including control reactions
with identical RNA concentration yet lacking RT en-
zyme. We subjected 2 μl of the RT(+) and RT(−) reac-
tions to standard PCR with the following cycling
parameters: 5′ 95 °C; 35 cycles of 50″ 95 °C, 50″ 53 °C,
1′ 72 °C; 10′ 72 °C. Amplification of an amplicon lo-
cated within the HERV-K(HML-2) gag gene utilized pre-
viously described mixes of 4 different forward primers
and 3 different reverse primers at relative ratios as previ-
ously described [30].
PCR amplification of rec and np9-related cDNAs was
as described [17].
Amplification of PCR products representing approxi-
mately 600 bp of the 5′ region of the HERV-K(HML-2)
env gene utilized the 4 different forward primers men-
tioned above for rec/np9 transcripts and the following
set of reverse primers: env600ntR1: 5′-ATT TAC CCG
TGG CCT GAG TG-3′; env600ntR2: 5′-ATT TAC
CCG TGG CCT AAG TG-3′; env600ntR3: 5′-ATT TAC
CTG TGG CCT GAG CG-3′; env600ntR4: 5′-ATT
TAC CTG TGG CCT GAG AG-3′; env600ntR5:
5′-ATT TTA TCT GTG GCC CGA GTG-3′;
env600ntR6: 5′-ATT CAT TTG TGA CCT GAG C-3′
mixed at relative ratios of 5:1:1:1:1:1. Cycling parameters
of the PCR were as described for the gag amplicon (see
above). All PCRs had a total volume of 50 μl each. We
analyzed results of RT-PCRs by electrophoresis in 1.5%
[w/v] 1xTAE agarose gels containing 0.4 μg/ml of eth-
idium bromide. We loaded 5 μl (out of 50 μl total PCR
volume) from PCRs with RT(+) reactions and 18 μl out
of 50 μl total PCR volume from PCRs with RT(−) reac-
tions onto the gel. Only RNA samples not displaying
PCR products in RT(−) control reactions were included
for further analysis. The strategy for generation of
HERV-K(HML-2) cDNA was unstranded, that is, inde-
pendent of transcriptional direction of loci.
cDNA sequencing and assignment to HERV-K(HML-2) loci
RT-PCR products from selected ALS and control samples
were cloned into pGEM T-Easy vector (Promega). Clones
with inserts were identified by colony-PCR. Plasmid DNAs
from randomly selected clones were purified and subjected
to Sanger DNA sequencing using a vector-specific T7 pri-
mer and Applied Biosystems 3730 DNA-Analyzer (Seq-IT
GmbH, Kaiserslautern, Germany). Poor quality sequences
were excluded from further analysis.
Assignment of cDNA sequences to HERV-K(HML-2)
reference and non-reference loci based on locus-specific
nucleotide differences followed previously established
procedures that generate a relatively unbiased and repro-
ducible identification of transcribed HERV-K(HML-2)
loci and their relative transcript levels ([17, 30], and un-
published results). We mapped cDNA sequences to the
human GRCh38/hg38 reference genome sequence as
provided by the UCSC Genome Browser [59, 60] as well
as to reported non-reference HERV-K(HML-2) se-
quences HERV-K113 [61], HERV-K111 (GenBank acc.
no. GU476554; [62]), the so-called “Venter locus” (Gen-
Bank acc. no. ABBA01159463; [17, 63]), and additional
polymorphic HERV-K(HML-2) type 1 and type 2
sequences recently reported by Wildschutte et al.
(Genbank acc. no. KU054272; KU054255; KU054265;
KU054266; ref. [10]). Numbers of nucleotide differences
of reference genome and non-reference HML-2 loci are
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depicted for the various RT-PCR amplicons in
Additional file 2: Figures S1-S4. For the sake of conveni-
ence, chromosomal locations of reference
HERV-K(HML-2) loci are given in this paper for human
genome sequence version GRCh37/hg19. Problems
assigning some of the cDNA sequences due to too few
nucleotide (nt) differences between some of the
HERV-K(HML-2) loci are addressed in the text.
Analysis of transcript levels by RT-qPCR
We analyzed in a blinded fashion transcript levels of
HERV-K(HML-2) by RT-qPCR employing combinations
of four forward and three reverse PCR primers amp-
lifying an approximately 620-bp region of the
HERV-K(HML-2) gag gene as previously described with
minor modifications [30]. Briefly, qPCR cycling parame-
ters were as follows: initial denaturation for 3 min at
95 °C, 40 cycles of 50 s at 95 °C, 50 s at 53 °C, 1 min at
72 °C, and final elongation for 10 min at 72 °C. Dupli-
cate samples were analyzed in a StepOne Real-Time
PCR system (Applied Biosystems) using Go Taq qPCR
MasterMix (Promega) and PCR primers at 200 nM each.
For all samples, GAPDH was used as an internal
normalization control, following the strategy of another
study of HML-2 expression associated with ALS [46].
PCR primers used were GAPDH Fwd: 5´-TGC ACC
ACC AAC TGC TTA GC-3′ and GAPDH Rev.: 5´-GGC
ATG GAC TGT GGT CAT GAG-3′. The run method
was as follows: 10 min at 95 °C, 40 cycles of 15 s at 95 °C
followed by 60 s at 60 °C. A melting curve was subse-
quently recorded to confirm the identity of amplified
products. We employed the ΔΔCt method [64] to deter-
mine relative differences in transcript levels. We defined
HERV-K(HML-2) transcript levels determined for
H9-human embryonic stem cells (hESCs) as 1, as these
cells overexpress HERV-K(HML-2) RNAs [65]. Transcript
levels were plotted as “Fold change in transcript level”
with respect to the transcript level in H9-hESCs (=1).
Standard deviations were calculated based on 4 data
points per sample derived from duplicate measurements
and a technical replicate for each sample [65, 66]. Scatter
plots showed no correlation between age at death or gen-
der of donors and relative HML-2 transcript levels
(Additional file 2: Figure S10).
Protein isolation from tissue samples and western blot
For protein extracts, tissues or cells were lysed in RIPA
buffer containing Mammalian Protease Inhibitor Cock-
tail and PMSF (Sigma) and homogenized with a Diage-
node Bioruptor. In the case of tissues, five 2.0 mm
diameter Zirconium Silicate Beads (Next Advance) were
added to the tubes. Samples were centrifuged at
12,000 rpm at 4 °C for 15 min to recover supernatant.
Western blotting and detection of proteins was
performed as described [67]. Monoclonal α-Env-TM
antibody was from Austral Biologicals (HERM-1811-5).
Peroxidase-conjugated secondary antibodies were from
Jackson ImmunoResearch Laboratories.
Results
Recently, Li et al. [46] found elevated expression of
HERV-K gag, pol, and env genes in brain tissue samples
of ALS patients. Immunostaining detected Env protein
in the large pyramidal neurons of the cortex and in the
anterior horn neurons of the spinal cord. Overexpression
of HML-2 Env protein was reported to exert effects in
human neurons as well as in a mouse model leading to
motor dysfunction. However, the actual HML-2 loci
transcribed in ALS are largely uncharacterized. The
identification of transcribed source HML-2 loci can pro-
vide important information on deregulated HML-2 loci
as well as HML-2 proteins potentially expressed in ALS
and normal controls.
To identify expressed HML-2 loci, we employed re-
cently established strategies based on Sanger DNA se-
quencing of PCR-derived amplicons targeting a region
within the gag gene, one within the env gene, and spliced
rec/np9 transcripts [17, 29, 30]. Briefly, the strategy in-
volved specific amplification of HML-2 transcript por-
tions by RT-PCR, followed by cloning of RT-PCR
products, random selection of insert-harboring clones,
and Sanger-sequencing of selected clones. cDNA se-
quences generated were then mapped to the human ref-
erence genome sequence (build GRCh38/hg38) and
non-reference polymorphic HERV-K(HML-2) sequences
(see the Methods section). We examined in our tran-
scription profiling a total of 32 bulk tissue samples from
motor cortex and occipital lobe brain regions, and cer-
vical or thoracic spinal cord sections of both diseased
patients and controls (Additional file 1: Tables S1, S2).
In the following, every number given in the text and tables
means a unique patient (except 33 and 60 which are each
used for two patients, as indicated in Additional file 1:
Table S1). We indicated in tables, in the main paper text
and in Additional file 1: Table S1 instances where different
tissue types were obtained from the same patient. The no-
menclature of patient samples is thus “patient number -
brain region”.
There is no established nomenclature for HERV loci.
Different designations of HERV-K(HML-2) loci can
therefore be found in the literature. We designate spe-
cific HML-2 loci by combining designations from two
established naming systems, one of which is based on
the location of HML-2 loci in chromosomal bands [68],
the other on approved designations of transcribed
HML-2 loci as assigned by the HUGO Gene Nomencla-
ture Committee (HGNC) [69]. For instance, a HML-2
locus designated “7p22.1” by ref. [68] and “ERVK-6” by
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HGNC [69] is now given as “chr7p22.1_K-6”. HML-2
loci without a HGNC designation are noted as “chromo-
somal band_K-*” or by their original popular
designation.
Identification of transcribed HML-2 loci based on a gag
amplicon
We amplified an approximately 620-nt region located
within the HML-2 gag gene region by RT-PCR, cloned the
cDNA, and performed Sanger DNA sequencing of ran-
domly selected insert-harboring plasmid clones [17, 30].
Our profiling of transcribed HML-2 loci based on a
gag region included 19 samples from 13 ALS patients
(11 motor cortex, 6 occipital region, 2 spinal cord)
and 9 samples from 7 controls (5 motor cortex, 2 oc-
cipital region, 2 spinal cord). Both motor and occipi-
tal tissue samples were available from 5 ALS patients
and 2 controls (Additional file 1: Table S2). A total of 820
cDNA sequences (522 from ALS patients and 298 from
controls) were generated from those samples and assigned
to HML-2 loci, with 8 to 51 (average 29) sequences ob-
tained per sample. We identified a total of 20 different
HML-2 loci as transcribed based on the gag-derived
cDNA sequences. Per sample, our profiling strategy iden-
tified, on average, 6.8 (minimum 4, maximum 11) HML-2
loci as transcribed. Assuming equal cloning efficiencies,
we observed very different relative cloning frequencies of
cDNA sequences originating from the various HML-2 loci
indicating different transcript levels of those loci in the
investigated samples.
Among all samples examined, transcripts from an
HML-2 locus in chromosome 3, here named
chr3q12.3_K-5, were most often identified, with an aver-
age relative cloning frequency of 49.8% (range 13–84.6%).
An HML-2 type 1 locus thus contributes a large propor-
tion of HML-2 RNA (see also below). Loci chr3q21.2_K-4
(12.1%; range 0–37.5%), chr7q34_K-15 (10.4%; range
05–32%) and chr19q13.12_K-29 (6.7%; range 0–18.2%)
were frequently detected in the tested samples. The
remaining 16 HML-2 loci were identified at relatively low
cloning frequencies (average 1.3%; range 0–30%) and
cDNAs from several of those loci were identified only
occasionally in some of the samples examined (Add-
itional file 1: Table S2). We then compared gag-der-
ived cDNA sequences separately to recently reported
human non-reference HERV-K(HML-2) sequences,
specifically the HERV-K111 [62] and polymorphic
HML-2 proviruses [10]. None of the gag-derived
cDNA sequences could be assigned with certainty to
those non-reference HML-2 sequences.
Notably, we did not obtain strong evidence for HML-2
loci differentially transcribed in ALS disease versus con-
trol conditions based on gag-derived transcription pro-
files of HML-2 loci. The four dominantly transcribed
HML-2 loci were identified at very similar relative fre-
quencies in both conditions (Table 1, Fig. 2). In detail,
when averaging disease versus controls, locus
chr3q12.3_K-5 was identified at relative average cloning
frequencies of 47.3% in ALS samples versus 55.1% in
control samples; locus chr3q21.2_K-4: 12.6% vs. 11.1%;
locus chr7q34_K-15: 10.6% vs. 10.1%; locus
chr19q13.12_K-29: 7.6% vs. 4.9%, with relatively small
ranges between samples (Additional file 1: Table S2).
There were only two HML-2 loci identified as tran-
scribed in ALS but not control samples, yet those loci
each had relative cDNA cloning frequencies of only 2
out of 522 cDNA sequences for all ALS-derived samples
(< 0.4%). The same was true for two HML-2 loci not
identified in the ALS state that were each identified by
only 1 out of 298 cDNA sequences in control samples.
Taken together, our gag-based analysis revealed a
number of transcribed HML-2 loci, some predominantly
transcribed, but with overall very similar transcription
profiles in ALS-derived samples compared to samples
from controls.
Identification of transcribed HML-2 loci based on cDNA
sequences from an env gene region
Next, we identified in a complementary approach tran-
scribed HML-2 loci from cDNA sequences derived from
the HML-2 env gene region. To do so, we designed a
PCR amplicon spanning the 292-bp indel region distin-
guishing type 1 and type 2 HML-2 loci, thus generating
PCR products of 330 bp and 620 bp, respectively.
Amplicons extended from the canonical start codon of
Env, Rec and Np9 downstream into the env gene region
(Fig. 1). PCR products should thus include both
unspliced full-length transcripts and spliced env
transcripts.
We examined 4 ALS patient samples (3 motor cortex,
1 spinal cord) and 3 control samples (2 motor cortex, 1
spinal cord). PCR products representing env gene tran-
scripts from type 1 or type 2 loci were cloned and a total
of 144 cDNA sequences were assigned to HML-2 se-
quences in the human reference genome and to recently
reported non-reference HML-2 sequences (Table 2). We
assigned, on average, 20.5 (10–40) cDNA sequences per
sample. Approximately 96% of cloned cDNA sequences
were derived from HML-2 type 1 loci. We note that this
skew is likely due to much lower amounts of RT-PCR
product from HML-2 type 2 loci (Additional file 2:
Figure S8) that subsequently yielded fewer plasmid
clones harboring type 2 locus-derived PCR products.
Higher amounts of HML-2 type 1 transcript amplified in
env RT-PCRs are in line with results from the gag-based
transcription profiling that identified type 1 locus
chr3q12.3_K-5 as predominantly transcribed. A total of
93 cDNA sequences were assigned with great confidence
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to 8 different HML-2 reference loci. Due to insufficient
numbers of nucleotide differences, we failed to assign a
total of 30 cDNA sequences unambiguously to one of
two different HML-2 loci located on chromosome 1
(locus chr1q22_K-7) and chromosome 5 (locus
chr5q33.3_K-10). The same applied to 3 cDNA se-
quences mapping inconclusively to two different HML-2
loci on chromosome 8p23.1 that are located within rela-
tively recently duplicated genome regions and therefore
display too few nt differences to permit unambiguous
mapping. A total of 18 cDNA sequences likely derived
from the so-called “Venter sequence” (GenBank acc. no.
ABBA01159463; see ref. [17]), based on one more nt dif-
ferences in the HERV-K111 sequence (see below).
Including the unambiguously assignable cDNA se-
quences, between 3 and 7 HML-2 loci per sample were
identified as transcribed (Table 2). Transcripts very likely
deriving from locus chr3q12.3_K-5 were identified in
each of the ALS-derived as well as in control samples,
with a total of 78 cDNA sequences assignable to that
locus, ranging from 28 to 77.5% of cDNA sequences per
sample. Also for each sample, between 12.5 and 32% of
a total of 30 cDNA sequences were assignable to the
chr1q22_K-7/chr5q33.3_K-10 loci.
Transcripts likely originating from locus chr3q13.2_K-3
were identified in 5 out of 7 samples, with relative
cloning frequencies up to 7.7%. Transcripts likely ori-
ginating from the Venter locus (rather than
HERV-K111, see above) were also identified in 5 out
of 7 samples, with relative cloning frequencies of up
to 28%. In addition, transcripts most likely derived
from HML-2 loci chr1p31.1_K-1, chr1q23.3_K-18,
chr3q21.2_K-4, chr5q33.3_K-10, chr11q23.3_K-20,
chr19q11_K-19, and the two inconclusive HML-2 loci
Table 1 Relative cloning frequencies of gag amplicon-derived cDNA sequences assignable to unique HERV-K(HML-2) loci*
Locus designation ALS Ctrl Type Env [aa] Rec/Np9 hg19
motor occi sc motor occ sc
chr1p31.1_K-1 1.57 1.49 2.90 4.17 1.56 1 606 Np9 chr1:75844857
chr1q22_K-7 0.31 1.43 0.72 1 606 Np9 chr1:155603549
chr3p12.3_K-* 1.04 2 242 chr3:75601670
chr3q12.3_K-5 52.20 39.55 58.57 60.14 52.08 64.06 1 263 Np9 chr3:101412824
chr3q13.2_K-3 1.56 1 434 Np9 chr3:112750203
chr3q21.2_K-4 11.01 15.67 7.14 13.04 13.54 1.56 2 Rec chr3:125611223
chr4p16.1a_K-* 0.63 0.72 1.04 2 158 chr4:9125672
chr4p16.1b_K-* 0.31 1.43 2.08 1.56 2 342 longer chr4:9661733
chr5q33.3_K-10 1.57 5.22 5.71 0.72 1 139 (969) chr5:156091809
chr7p22.1_K-6 0.63 2 699 (f-l) Rec chr7:4637944
chr7q22.2_K-14 0.94 1.49 2.86 2.17 1.04 3.13 del chr7:104392150
chr7q34_K-15 8.49 9.70 8.57 9.42 10.42 4.69 del chr7:141454695
chr8p23.1a_K-* 3.46 10.45 1.04 2 264 chr8:12081367
chr8p23.1b_K-* 5.35 2.24 7.81 2 264 chr8:12323877
chr10p14_K-16 1.89 2.99 2.86 2.17 7.81 2 286 Rec chr10:6873520
chr11q12.3_K-27 2.83 2.99 3.62 3.13 6.25 2 337 chr11:62148198
chr11q22.1_K-25 0.94 2 661 chr11:101567880
chr19q13.12_K-29 6.92 8.21 11.43 3.62 10.42 2 206 chr19:37604891
chr21q21.1_K-23 0.31 0.72 1 197 Np9 chr21:19940039
chr22q11.21_K-24 0.63 1 606 Np9 chr22:18934451
# cDNA sequences 318 134 70 138 96 64
# samples 11 6 2 5 2 2
*Designations of HML-2 loci identified as transcribed are given in the left column. Relative cloning frequencies of cDNA sequences from the HML-2 gag amplicon
assignable to either of those loci are summarized for motor cortex (motor), occipital region (occi) and spinal cord (sc) tissue samples from patients with ALS and
from controls. Total numbers of cDNA sequences assigned for each tissue group and numbers of samples analyzed per tissue group are given in the two bottom
lines. Detailed cloning frequencies for each sample are given in Additional file 1: Table S2. For each HML-2 locus, provirus type 1 or 2, the length of the potentially
encoded Env protein in number of amino acids (see also Fig. 2) and potential coding capacity for Rec or Np9 proteins are shown in the columns that follow. Note
that locus chr7p22.1_K-6 encodes a canonical full-length (f-l) Env protein of 699 aa, and locus chr5q33.3_K-10 potentially encodes an Env protein portion of
approximately 139 aa, while the locus also harbors a longer Pro-Env ORF of 969 aa (see text). The rightmost column gives the chromosomal location of the
respective HML-2 locus in human reference genome sequence GRCh37/hg19. For the sake of brevity, only one nucleotide position (approximately the central
position of the gag amplicon) is given. Relative cloning frequencies are also depicted in Fig. 2
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Fig. 2 Relative transcript levels of HML-2 loci in ALS and control samples deduced from the gag amplicon. Numbers are based on relative cloning
frequencies of gag amplicon-derived cDNA sequences assignable to different HML-2 loci. Results for tissue samples from motor cortex (motor),
occipital cortex (occi) and spinal cord (sc) are each summarized as percentages. Numbers of patients and control donors per tissue type are indicated
above each bar. Detailed gag amplicon-derived cDNA cloning frequencies for each tissue sample are provided in Additional file 1: Table S2
Table 2 Relative cloning frequencies and locus origins of cDNA sequences from an env gene 5′ region*
locus designation ALS Ctrl Type Env Rec/Np9 hg19
motor motor motor sc motor motor sc
89-Mot 62-Mot 64-Mot 802-SC 1509-Mot 73-Mot 4263-SC
chr1p31.1_K-1 4.00 7.69 4.00 1 606 Np9 chr1:75844857
chr1q23.3_K-18 4.00 1 553 chr1:160667241
chr3q12.3_K-5 62.50 77.50 70.00 28.00 53.85 40.00 40.00 1 263 Np9 chr3:101412824
chr3q13.2_K-3 6.25 2.50 7.69 6.67 4.00 1 434 Np9 chr3:112750203
chr3q21.2_K-4 13.33 2 Rec chr3:125611223
chr5q33.3_K-10 8.00 1 chr5:156091809
chr11q23.3_K-20 6.67 1 431 chr11:118594283
chr19q11_K-19 6.67 2 699 chr19:28131235
Venter 7.50 10.00 28.00 15.38 20.00 1 452
chr1:155…/chr5:156… 31.25 12.50 20.00 24.00 15.38 13.33 32.00
chr8:80…/chr8:12… 4.00 13.33
# cDNA sequences 16 40 10 25 13 15 25
*A total of 4 samples from ALS patients and 3 samples from controls were examined. A number of cDNA sequences could not be assigned with confidence to
either one of two different HML-2 loci on chr1:155,598,877–155,599,165 or chr5:156,087,137–156,087,425, and chr8:8,061,161–8,061,741 or locus chr8:12,318,971–
12,319,551. Note that the skew towards type 1 loci is caused by lower amounts of RT-PCR product from type 2 loci and therefore relatively few clones with type
2-derived PCR-product (see the main paper text). See also legends to Tables 1 and 2 for more details
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in chromosome 8p23.1, were identified less frequently
and in fewer samples (Table 2).
In sum, and in agreement with results for the
gag-based transcription profiling, we did not observe ap-
parent differences when comparing HML-2 loci tran-
scribed in ALS-derived versus control samples.
Identification of HML-2 loci generating rec and np9
transcripts
Recent studies suggested biological roles for
HML-2-encoded Rec and Np9 proteins that are gener-
ated from additional splicing events of the HML-2 env
transcript. Previous studies found rec and np9 tran-
scripts from different HML-2 loci in many human tissue
types, including the brain (for instance, see ref. [17]).
We therefore examined rec and np9 transcripts
present in ALS and control samples using an RT-PCR
strategy amplifying larger portions of rec and np9
exons 2 and 3 (Fig. 1), as recently described [17].
RT-PCR products indicative of rec and np9 transcripts
could be amplified from all examined ALS and con-
trol samples. However, relative amounts of rec and
np9 RT-PCR products were variable between samples
(Additional file 2: Figure S5).
Further employing our established strategy of identifi-
cation of HML-2 loci generating rec or np9 transcripts
by cloning and sequencing their cDNAs [17], we investi-
gated 5 ALS patient (2 motor cortex, 3 spinal cord) and
2 control samples (1 motor cortex and spinal cord each)
and a total of 67 rec and 144 np9 cDNA sequences from
these samples (Table 3). Apart from one rec cDNA
sequence assignable to locus chr3q21.2_K-4 (sample
5458-SC), the remaining 66 cDNA sequences derived
from a HML-2 locus in chromosome 5, here named
chr5q15_K-31, that represents a retrotransposed rec
mRNA apparently generated by the LINE-1 (L1)
non-LTR retrotransposon machinery in trans [17, 70].
Transcription of that HML-2 locus is presumably
driven by a flanking non-HML-2 promoter. One out
of 67 cDNA sequences isolated from a normal control
sample displayed a best match to locus
chr3q21.2_K-4.
The HML-2 locus origins of np9 transcripts were
more complex. A total of 5 different HML-2 loci were
found to generate np9 transcripts. Locus chr3q12.3_K-5,
a type 1 locus preferentially transcribed based on our
gag amplicon data (see above), was found to generate
np9 transcripts in all samples examined, yet with quite
variable relative cloning frequencies ranging from 5 to
97%. An np9 transcript from a HML-2 type 1 locus on
chromosome 22, chr22q11.21_K-24, was identified at
lower relative frequencies in one ALS sample (8%;
sample #802-SC) and a control sample (4%; sample
#5458-SC) (Table 3).
Notably, we also identified a total of 5 np9-like
transcripts in two ALS and one control samples that
most likely were generated not from a type 1 locus
but from type 2 locus chr3q21.2_K-4 (second highest
relative cloning frequency in the gag-based profiling).
More detailed analysis of particular cDNA sequences
indicated that the np9-like transcript from type 2
locus chr3q21.2_K-4 was generated by splicing of an
intron (that conformed to the GT-AG rule) beginning
from the canonical rec SD2 site, but skipping the ca-
nonical rec/np9 SA2 site and instead using an alterna-
tive site located 260 nt further downstream within
the 3′ LTR (Fig. 3).
Several np9 cDNA sequences did not map to HML-2
loci in the human reference genome but displayed best
matches to non-reference HML-2 loci. Specifically, 2, 11
and 46% of np9 cDNA sequences from three different
ALS patient samples (32-Mot; 35-Mot; 802-SC) and 17%
of cDNA sequences from a control individual (5458-SC)
best matched the recently described HERV-K111 se-
quence [62]. For those cDNA sequences, intron bound-
aries within the env gene region were in accord with a
recent observation that the canonical np9 SA2 site is
skipped due to a AG→GG mutation in the HERV-K111
sequence in favor of another AG located 7 bp down-
stream [17]. Thus, respective cDNA sequences isolated
from three ALS samples and a control sample most
likely derived from HERV-K111.
On the other hand, 68 and 17% of np9 cDNA se-
quences in one ALS patient sample, (35-Mot) and in
a control sample (5458-SC), respectively, best
matched the “Venter sequence” that is represented
only by a partial HML-2 type 1 locus sequence entry
(Genbank acc. no. ABBA01159463). That “Venter se-
quence” was also identified recently as generating np9
transcripts in human tissue types including brain [17].
Twelve np9 cDNA sequences could not be assigned
with certainty to HML-2 loci in the human reference
sequence or to non-reference HERV-K111 or “Venter”
sequences.
Taken together, rec and np9(−like) transcripts could be
identified in ALS and control samples without signifi-
cant differences. Locus chr5q15_K-31, representing a
retrotransposed rec mRNA, generated the dominant rec
transcript in all the investigated samples. A limited num-
ber of HML-2 loci generated np9-like transcripts with
np9 transcripts from locus chr3q12.3_K-5 being present
in all samples. Locus chr22q11.21_K-24 and the
non-reference HERV-K111 and “Venter” loci added vari-
able relative numbers of transcripts and comprised the
majority of np9 transcripts in two samples. A cDNA
variant of a length similar to that of np9 was character-
ized as an alternatively spliced transcript likely produced
from HML-2 type 2 locus chr3q21.2_K-4.
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Fig. 3 (See legend on next page.)
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Quantification of HERV-K(HML-2) transcript levels in ALS
and control tissues by RT-qPCR
Next, we measured overall levels of HERV-K(HML-2)
transcripts by RT-qPCR, employing the above men-
tioned amplicon within HML-2 gag, for a total of 108
ALS and control tissue samples employing previously
established strategies [30, 66]. Among these, we assayed
16 cerebellum tissue samples, with 9 of those derived
from ALS patients and 7 derived from controls, 30 sam-
ples (15 ALS; 15 controls) from thoracic or cervical
spinal cord, 35 samples (23 ALS; 12 controls) from
motor cortex, 19 samples (14 ALS; 5 controls) from oc-
cipital cortex, and 8 samples from hippocampus, all of
the latter from ALS patients. For the purpose of com-
parison, HML-2 transcript levels were also determined
for H9 human embryonic stem cells (H9-hESCs) [57],
human embryonic fibroblasts (HEFs, obtained from
ATCC), and HeLa cervical adenocarcinoma cells. Tran-
script levels were normalized based on GAPDH tran-
script levels co-determined for each sample (following
the strategy of ref. [46]). Since HERV-K(HML-2) has
previously been found to be highly expressed in hESCs,
induced pluripotent stem cells, and early human em-
bryogenesis [25, 65], transcript levels determined for
H9-hESC cells were furthermore defined as 1 and other
transcript levels are given relative to that reference. For
comparison with HERV-K(HML-2) levels, we also
assayed in all samples transcript levels of HERV-W
(Additional file 2: Figure S6) using two previously de-
scribed primer sets within the HERV-W env gene region
[71]. HML-2 transcript levels were determined in dupli-
cate for one biological replicate for each brain and spinal
cord sample and averaged. There were 4 samples for
which only one instead of four data points could be ob-
tained, presumably due to very low HERV-K(HML-2)
transcript levels. These were included in our analyses.
We considered all measurements of sample-specific
transcript levels as real and did not omit possible out-
liers, and we detected no effect of these on data signifi-
cance. Furthermore, in light of lower RIN values of some
RNAs, we also assessed effects of RNA quality on our
analyses by plotting RIN values versus RT-qPCR Ct-va-
lues of GAPDH. Notably, we could not detect a signifi-
cant effect of RNA quality when the various tissue types
were considered separately (Additional file 2: Figure S9).
However, a mild effect (R2 = 0.38) of RNA quality on
Ct-values was observed when combining RIN and Ct-va-
lues from all samples. A key point is that the omission
of samples with lower RINs did not affect our conclu-
sions. In fact, even RNAs with the lowest RIN values
produced C
t
-values comparable with RNAs with higher
RINs (Additional file 2: Figure S9). See also, for instance,
ref. [59] on the validity of samples with reduced RIN
values for endpoint RT-PCR and RT-qPCR experiments.
Overall, HML-2 transcript levels were considerably dif-
ferent between samples and tissue types (Fig. 4). For in-
stance, average transcript levels ranged between 0.6% for
occipital region tissue samples from controls and 21% for
ALS-derived cerebellum tissues relative to H9-hESC.
When compared to HEFs (not shown in Fig. 4), transcript
levels were approximately ten-fold higher in cerebellum,
while spinal cord and motor cortex tissues were in the
same range and two-fold higher, respectively. Transcript
levels for occipital and hippocampal region samples were
lower compared to HEFs and rather similar to Hela cells,
which were only 0.007% that of H9-hESC (not shown
in Fig. 4). HML-2 transcript levels measured for spe-
cific samples within tissue types also varied consider-
ably (Fig. 4). For instance, transcript levels in the 30
cortical spinal cord tissue samples ranged from 0.17
to 7%, those in the 35 motor cortex tissue samples
from 0.2 to 21.6%, and those in the 16 cerebellum tis-
sue samples from 0.24 to 56% relative to the levels
detected in H9-hESC.
More importantly, our analysis did not reveal signifi-
cantly different transcript levels when comparing ALS
and control samples within each tissue type for p < 0.05
in a Student’s t-test. A Shapiro-Wilk test did not confirm
normal distribution for transcript levels measured in
ALS and normal control-derived motor cortex tissue
samples. A Wilcoxon-signed-rank test applied to those
samples’ transcript levels also established no significant
differences (p > 0.05) for those tissue types. In the case
of HERV-W, while overall transcript levels were much
higher compared to HERV-K(HML-2), significantly dif-
ferent transcript levels were detected for the 14 ALS ver-
sus 5 control occipital cortex samples only (p < 0.04)
(Additional file 2: Figure S6). However, further investiga-
tions of HERV-W transcription were beyond the scope
of this project.
(See figure on previous page.)
Fig. 3 Alternatively spliced transcripts of np9-typical length likely generated from HML-2 type 2 locus chr3q21.2_K-4. Five cDNA sequences (with
sequences of PCR primers deleted) isolated from 2 different ALS and one control sample are multiply aligned with the sequence of HML-2 locus
chr3q21.2_K-4 and with respect to 5′ and 3′ exon sequences within the env gene region. Boundaries of the 292-bp region distinguishing HML-2
type 1 and type 2 loci and splice donor (SD) and splice acceptor (SA) sites of canonical rec splicing, the Env/Rec/Np9 translational start site, and
the 5′ end of the 3’ LTR are indicated. Note that most of the env gene (i.e. the rec intron 2, see Fig. 1) is omitted from the figure, indicated by the
dashed line between the two alignment blocks. Also note that the canonical np9 SD within the env gene is missing in locus chr3q21.2_K-4
(see also ref. [14])
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Taken together, our quantification of overall
HERV-K(HML-2) transcript levels in more than 100
ALS-derived (40 donors) and control tissue samples
(27 donors) revealed considerable variability in tran-
script levels between samples and tissue types, yet no
significant differences in HML-2 transcript levels
when comparing ALS-derived and control samples
within tissue types.
Env gene-derived proteins potentially encoded by
transcribed HERV-K(HML-2) loci
Several HERV-K(HML-2) loci in the human genome are
coding-competent for functional proteins. Various pro-
teins encoded by the HML-2 env gene region have been
identified recently and some of those proteins may inter-
fere with cellular processes (see the Background section).
In light of the reported link between HERV-K(HML-2)
Env protein expression and motor neuron toxicity [46],
we were interested in determining which env
gene-derived proteins could potentially be encoded by
HML-2 loci identified as transcribed by our gag or env
gene-derived cDNA sequencing.
We first examined the coding competence of tran-
scribed HML-2 loci for Env proteins. Canonical
full-length HML-2 type 2 Env protein is 699 amino acids
(aa) in length 79 kDa and can be processed into a stable
signal peptide (Env-SP) of approx. 13 kDa [36], a sur-
face/outer membrane (SU/OM) domain of approx.
41 kDa, and a transmembrane domain (TM) of approx.
26 kDa due to cleavage by furin endoprotease (see se-
quence #3 in Fig. 5). Of note, TM protein may run at a
higher molecular weight if glycosylated. HML-2 type 1
loci may encode a shorter Env protein variant of ap-
proximately 63 kDa lacking N-terminal portions sur-
rounding the 292-bp sequence that is missing in HML-2
type 1 loci, while still including large portions of SU/
OM and the TM domains in cases where the open read-
ing frame (ORF) extends downstream into the env gene
(see #12 and #19 in Fig. 5). Processing of the TM do-
main has been shown experimentally for such type
1-encoded Env variants [35].
Notably, we found that transcribed HML-2 loci poten-
tially encode a diverse array of Env protein variants (Fig. 5).
For instance, type 2 loci chr7p22.1_K-6 and chr19q11_K-19
(sequences #3 and #9 in Fig. 5) potentially encode a canon-
ical Env protein while type 2 locus chr11q22.1_K-25 (#8 in
Fig. 5) potentially encodes an Env protein truncated by 38
aa at the C-terminus. Loci 1q22_K-7 (#12, Fig. 5) and
Fig. 4 Boxplots of HERV-K(HML-2) overall transcript levels as measured by RT-qPCR. Overall HML-2 transcript levels were measured in samples
from various tissue types from ALS patients and controls employing a previously established strategy amplifying a region within the HML-2 gag
gene [30]. The left boxplots depict normalized transcript levels determined for ALS and control samples from cerebellum. Note the higher relative
and much more variable transcript levels in cerebellum. The right boxplots depict normalized HML-2 transcript levels for ALS and control samples
from tissue types other than cerebellum. Boxplots depict for each tissue type maximum and minimum values, 95th, 75th, 25th and 5th percentiles,
and mean and median, as well as measured transcript levels. Note the break in the Y-axis and that hippocampus included only ALS-
derived samples. HML-2 transcript levels are given relative to HML-2 transcript levels co-determined for H9-hESC (set to 1, see text). There
were no significantly different transcript levels when comparing ALS and control samples within each tissue type for HML-2 (see the
paper text). Significant differential expression was found only for HERV-W transcripts in ALS occipital region samples (see Additional file 2:
Figure S6)
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chr22q11.21_K-24 (#19, Fig. 5) may encode a “full-length”
type 1-like Env protein while type 1 locus chr1q23.3_K-18
(#13, Fig. 5) may encode a similar protein truncated by 28
aa at the C-terminus. HERV-K111 (#20, Fig. 5) and the
Venter locus (#21, Fig. 5), both of type 1, may encode
Pol-Env fusion proteins reaching just 38 aa into the
Env-TM domain. Other HML-2 type 1 and type 2 loci
would encode Env(−like) proteins more severely truncated
either at the N- or the C-terminus (Fig. 5). A recent
ALS-related study [42] reported an HML-2 locus in human
chromosome 3q13.2 to harbor an Env ORF. Our own ana-
lysis could not confirm such an Env ORF. Rather, this
HML-2 type 1 locus, designated chr3q13.2_K-3 in our ana-
lysis, harbors a partial internal Env ORF consisting of SU/
OM and TM portions, yet lacking 118 aa of its N-terminus
and 172 aa of its C-terminus. A second, even shorter ORF
comprising approximately 200 aa within Env-TM is also
predicted for the chr3q13.2_K-3 locus (#15, #16, Fig. 5).
When taking cloning frequencies of cDNAs from the
various HML-2 loci as a rough measure of relative tran-
script levels, we note that HML-2 loci encoding
full-length or near full-length Env proteins, either of
type 1 or type 2, appear transcribed at very low levels
(#6, #8, #9, #12, #13, #19, Fig. 5) compared with ele-
ments containing more truncated open reading frames.
Highest relative cDNA cloning frequencies were ob-
served, for example, for locus chr3q12.3_K-5 (53%), po-
tentially translating an internal SU/OM portion of
approx. 27 kDa, and locus chr19q13.12_K-29 (6.8%), po-
tentially translating an Env-SP/SU/OM portion of
approxately 23 kDa (#14, #10, Fig. 5).
Taken together, a number of Env protein variants com-
prising internal Env portions and lacking N- or
C-terminal portions of variable length may be expressed
in ALS and controls. However, canonical full-length
HML-2 Env protein is likely expressed at relatively low
levels because HML-2 loci capable of generating canon-
ical full-length HML-2 Env protein are very poorly tran-
scribed, at least in samples analyzed for this study.
Coding-competence of transcribed HML-2 loci for Rec and
Np9 proteins
We next were interested in determining if Rec and
Np9 proteins could potentially be encoded by HML-2
loci transcribed in our samples. We based our ana-
lysis on recent surveys of coding capacities of HML-2
Fig. 5 Env(−like) proteins potentially encoded by HERV-K(HML-2) loci identified as transcribed by this study. A full-length, canonical Env
protein of 699 aa, as encoded by the HERV-K(HML-2.HOM) type 2 locus, is represented by sequence chr7p22.1_K-6 (=HERV-K(HML-2.HOM);
Genbank acc. no. AF074086; ref. [89]). Grey boxes indicate locations of ORFs within the env gene region relative to full-length Env.
Amino acid sequence differences among the various sequences are highlighted. Protein sequences as encoded by type 2 and type 1 loci
are separated accordingly. The 292-bp indel region distinguishing type 1 and type 2 proviruses on the DNA level is depicted for the
topmost sequence. Signal peptide peptidase (SPPase) and furin cleavage sites are annotated and define signal peptide (SP), surface/outer
membrane (SU/OM) and transmembrane (TM) regions, if proteins are so processed. Note that the size of the full-length TM domain is
around 26 kDa. Predicted protein masses of selected potential TM variants are indicated. Three HML-2 loci, labelled “*” left of sequence
names, were identified as transcribed based on a PCR amplicon within the env 5′ region. Two different Env partial proteins may be
encoded by HML-2 locus 3q13.2_K-3 and are named ORFa and ORFb. HML-2 loci chr1p31.1_K-1, chr5q33.3_K-10, HERV-K111 and the
Venter locus harbor longer Pol-Env fusion ORFs extending into upstream proviral regions (see the text). Most of those proteins’ N-terminal
portions are omitted from the figure. Relative cloning frequencies of locus-specific cDNAs, as determined by the gag amplicon (see Table 1), are given
right of the sequence names. Note that locus chr3q12.3_K-5 was found transcribed at the highest relative level (~ 53%)
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loci for Rec or Np9 proteins, taking into account
splice donor and acceptor signals and the presence of
ORFs in our mRNA sequences, together with recent
findings regarding rec and np9 mRNAs found in vari-
ous human tissue types [16, 17].
We identified three transcribed HML-2 loci potentially
encoding Rec protein, specifically type 2 loci chr3q21.2_K-4
(see also below), chr7p22.1_K-6, and chr10p14_K-16. Rela-
tive cDNA cloning frequencies of those three loci were, for
all samples combined, 11.3, 0.2 and 2.4%, respectively, and
without obvious differences when comparing ALS and con-
trol samples. Predicted amino acid (aa) sequences of re-
spective Rec proteins displayed a number of aa differences
compared with each other. Interestingly, several of those
differences were located within previously identified func-
tional domains of Rec (Fig. 6a).
Our PCR-based approach had identified locus
chr5q15_K-31, a retrotransposed rec mRNA [17], as pre-
dominantly generating rec-like transcripts (see above).
However, locus chr5q15_K-31 displays a stop codon 19
aa into the Rec encoding region and therefore likely does
not encode Rec protein [17].
Another potentially encoded Rec-like protein originat-
ing from locus chr3q21.2_K-4 (see above) is likely
slightly shortened at the C-terminus due to an alterna-
tive, np9-like splicing of transcripts (see Fig. 3). This
protein would lack the C-terminal 17 aa compared to ca-
nonical Rec protein as encoded, for instance, by locus
chr7p22.1_K-6 (Fig. 6b). As locus chr3q21.2_K-4 harbors
the canonical rec/np9 splice acceptor site, it is unclear
whether locus chr3q21.2_K-4 could encode both the ca-
nonical length and the shorter Rec proteins.
We furthermore identified six HML-2 loci potentially
encoding Np9 protein, specifically loci chr1p31.1_K-1,
chr1q22_K-7, chr3q12.3_K-5, chr3q13.2_K-3, chr21q21.1_K-23,
and chr22q11.21_K-24 (Fig. 6c). The gag-based tran-
scription profiling had produced relative cloning fre-
quencies of 2, 0.4, 53, 0.1, 0.2, and 0.2%, respectively,
for those loci. Therefore, locus chr3q12.3_K-5 would
be transcribed predominantly compared to other Np9
potentially encoding loci. A higher relative transcript
level of locus chr3q12.3_K-5 is also supported by our
PCR-mediated approach, which identified np9 spliced
transcripts from locus chr3q12.3_K-5 in all six samples ex-
amined, at an average relative cDNA cloning frequency of
54% (Table 3). Furthermore, chr3q12.3_K-5 derived cDNA
sequences from the env gene 5′ region were frequently
seen (53%) (see Table 2). Of further note, Np9 protein
Fig. 6 HERV-K(HML-2) Rec and Np9 proteins potentially encoded by transcribed HML-2 loci. Respective amino acid sequences are aligned for (a) Rec
and (c) Np9 proteins. Amino acid differences between sequences are highlighted. Previously described domains interacting with other cellular proteins
are indicated (see, for instance, ref. [12], and references therein). The chimeric Rec/Np9/Env-like protein potentially encoded by HERV-K111 and the
“Venter locus” is depicted in more detail in Fig. 7. b A shortened Rec-like protein potentially encoded by alternative np9-like splicing of transcripts from
HERV-K(HML-2) type 2 locus chr3q21.2_K-4 is compared separately to the Rec protein sequence as encoded by HML-2 locus chr7p22.1_K-6. Note that
transcripts from the potentially Rec-encoding locus chr3q21.2_K-4 were identified at an average relative frequency of 10.3% for the gag amplicon and
less frequently for the rec/np9 and env amplicons. Also note that transcripts from the potentially Np9-encoding locus chr3q12.3_K-5 were identified at
relative average frequencies of 55% for the gag, rec/np9, and env amplicons (see the text and Tables 1–3)
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encoded by locus chr3q12.3_K-5 does not display aa dif-
ferences within previously reported Np9 functional do-
mains (Fig. 6b).
It is therefore conceivable that canonical and variant
Rec and Np9 proteins capable of exerting previously re-
ported cellular effects are expressed in both ALS and
normal control samples.
Potential expression of chimeric proteins consisting of
portions of Env, rec and Np9
Our transcription profiling also identified transcribed
HML-2 loci and alternatively spliced transcripts that
may encode chimeric proteins consisting of truncated
portions of Env, Rec and Np9 proteins.
We identified transcripts likely derived from the
HERV-K111 and Venter loci, both of which have been
identified in previous studies as transcribed [17, 62]. Both
loci potentially encode a protein from an np9-like spliced
transcript that is similar to Env and Rec protein at the
N-terminus and to Env protein at the C-terminus, based
on sequence comparisons. The chimeric protein would
harbor a previously reported TZFP-interacting domain
[24] within the Rec-like portion of the protein (Fig. 7a). As
up to 46% of cDNA sequences could be assigned to
HERV-K111 and up to 68% of cDNA sequences could be
assigned to the Venter locus (while some samples exam-
ined lacked transcripts assignable to either sequence), it is
conceivable that such chimeric protein variants are
expressed in some of the ALS and control samples.
We furthermore noted an ORF of 155 aa in length
from locus chr4p16.1_K-* that could potentially en-
code a protein consisting of 87 aa at the N-terminus
similar to HML-2 Env, with the remaining protein
displaying higher similarities to Np9 protein. Several
Fig. 7 Chimeric Rec/Np9/env proteins potentially encoded by HERV-K111, the Venter locus and locus chr4p16.1b_K-*. a Amino acid sequences of
proteins potentially encoded by spliced env gene transcripts of HERV-K111 and the Venter locus are aligned to the canonical Env protein sequence of
locus chr7p22.1_K-6 (=HERV-K(HML-2.HOM); Genbank accession number AF074086; ref. [89]). Note that only the N-terminal 60 aa and the C-terminal
99 aa of chr7p22.1_K-6 Env protein are shown, with both alignment blocks separated by a dashed line. b Chimeric Env/Rec/Np9 protein potentially
encoded by a spliced transcript from locus chr4p16.1b_K-* multiply aligned with Env/Rec and Np9 protein sequences as encoded by loci chr7p22.1_K-
6 (aa 1–87 are shown) and chr1p31.1_K-1. Previously described functional domains within Rec and Np9 are indicated. Differences between protein
sequences are highlighted. Dot matrix comparisons below the alignment further depict sequence similarities of respective proteins. Parameters of
sequence comparisons were as follows: window size: 5; Min. % score: 50; Hash Value = 1; pam250 scoring matrix
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previously reported functional domains would be
present in this chimeric protein but with various aa
differences (Fig. 7b). However, we also note that the
average relative cloning frequency of transcripts from
locus chr4p16.1_K-* was just 0.6%.
HERV-K(HML-2) Env protein expression in ALS and control
tissues
We next used a monoclonal α-Env antibody
(HERM-1811-5, Austral Biologicals), recognizing the
HML-2 Env C-terminus (for instance, see [72–75]), to
assess Env protein expression in ALS and normal spinal
cord, motor cortex, cerebellum and frontal cortex sam-
ples. The samples and numbers examined for each re-
gion are summarized in Additional file 1: Table S1 and
representative Western blot results are shown in
Additional file 2: Figure S7).
In 2102Ep cells, a human embryonic germ cell
teratocarcinoma line that has a transcriptome very
similar to hESC [76, 77], this antibody strongly de-
tects a single prominent band of approximately
80 kDa consistent with full-length HERV-K(HML-2)
Env protein and occasionally a faint band of about
52 kDa (Additional file 2: Figure S7). A dilution series
shows that, using our Western blotting conditions,
the antibody is able to detect full-length Env in as lit-
tle as 6 μg of total cell lysate. Immunofluorescence
staining of fixed 2102Ep cells showed full-length
HERV-K(HML-2) Env protein to be predominantly
cytoplasmic, with some concentration in nucleoli
(Additional file 2: Figure S7).
However, full-length Env protein was not detected
in any brain or spinal cord samples analyzed, even
when 50 μg of whole cell lysate was loaded per well.
In a subset of spinal cord and cerebellum samples,
27 kDa bands of varying intensities and consistent in
size with the unglycosylated HML-2 Env-TM frag-
ment were seen. In some of these samples, a smaller
and fainter 13 kDa band was also occasionally seen.
While this size might indicate Env-SP protein, Env-SP
and Env-TM protein have no overlapping sequence
and could not both be detected by the HERM-1811-5
monoclonal antibody. Previous studies using cell lines
have reported that this antibody detects protein spe-
cies consistent in size with glycosylated Env-TM
(32 to 42 kDa) [73–75]. Kammerer et al. [78] re-
ported that this antibody recognized a single epitope,
FEASK, within the TM protein. In several of our
samples, bands ranging in size from 55 to 65 kDa
and of unknown origin were also seen. Contreras-Galindo
et al. [72] previously reported that HERM-1811-5 anti-
body also detects, in NCCIT cells, an approximately
55 kDa band consistent with Env-SU.
In summary, Western blotting, like our RNA
analyses, suggests that full-length Env protein is
expressed at very low levels in ALS or control brain
and spinal cord tissues. However, truncated protein
species may bear further investigation when consi-
dering a role for HML-2 Env in ALS etiology and
progression.
Discussion
The human endogenous retrovirus group HERV-K(HML-2)
has recently been implicated in ALS. Previously, a total of 7
HML-2 loci were identified as preferentially transcribed in
ALS patients based on cDNA sequences from an RT-PCR
amplicon located within the HML-2 polymerase gene [42].
HML-2 Envelope protein was also reported to be expressed
in cortical and spinal neurons of ALS patients and to cause
motor neuron toxicity following its expression in stem
cell-derived human neurons and in a transgenic mouse
model that displayed ALS-typical motor neuron and behav-
ioral anomalies. RNA-Seq analysis of several ALS and con-
trol samples furthermore identified a great number of
HML-2 loci (as many as 54) to be transcribed in ALS and
controls. Three HML-2 loci were found transcribed at
somewhat higher levels in ALS versus controls, yet with only
modest statistical support [46].
As described in the Background section, there is no
established optimal strategy for describing transcrip-
tion of the approximately 70 reference genome and
non-reference genome HML-2 loci identified so far
[10, 17, 30, 68]. RNA-Seq generating relatively short
reads poses considerable detection biases since evolu-
tionarily younger HML-2 are more difficult to identify
because of fewer nucleotide differences between loci.
Furthermore, a number of HERV sequences are em-
bedded in longer gene transcripts. This may lead to
misinterpreting the increased mRNA levels of a gene
as autonomous upregulation of its resident HERV se-
quence. In the case of LINE-1 retrotransposons, for
example, Deininger et al. [79] analyzed RNA-Seq data
from HeLa cells and found that greater than 99% of
LINE-1-related cDNA sequences were within other
RNAs and likely not derived from autonomous tran-
scription from an L1 promoter.
Thus, an as accurate as possible identification of tran-
scribed and potentially deregulated HML-2 loci is funda-
mental to understanding which HML-2 proteins, as well
as their actual encoded amino acid sequences, may be
expressed in disease versus normal conditions. To con-
tribute to a better understanding of HML-2 transcription
and HML-2 proteins potentially expressed in the ALS
context, we identified transcribed HML-2 loci by employ-
ing previously established Sanger sequencing-based strat-
egies [17, 29, 30] that target three different regions of the
HML-2 proviral genome and using primer sets
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compensating for nt differences between HML-2 loci
within respective primer binding regions. Our RT-PCR
and Sanger sequencing-based approach identifies tran-
scribed HML-2 loci independent of sense or antisense
transcription of respective loci, the latter potentially being
due to either antisense promoter activity initiating within
the 3′ LTR or a promoter in DNA flanking an HML-2
locus. A recent RNA-Seq-based analysis of HML-2 loci
transcribed in the GCT-derived cell line Tera-1, a line that
displays a relatively high level of HML-2 transcription,
identified some HML-2 loci as antisense transcribed, in-
cluding loci identified in our present study [49]. Some of
those loci appear to generate spliced rec or np9 tran-
scripts, specifically loci 1p31.1_K-1, 1q23.3_K-18,
chr3q12.3_K-5, 5p13.3, and 12q14.1_K-21 as revealed here
and in a recent study [17]. Because such spliced rec and
np9 transcripts can only be generated from HML-2 loci
that were transcribed in sense direction it remains to be
examined in more detail which HML-2 loci can be tran-
scribed in sense or antisense direction, or both. Analogous
with this, human LINE-1 non-LTR retrotransposons also
harbor sense and antisense promoters [80].
Our analysis of 32 brain and spinal cord tissue sam-
ples from 22 donors identified a total of 24 different
HML-2 loci as transcribed. As in previous analyses,
there were clearly different relative cloning frequen-
cies of cDNAs from different HML-2 loci: these can
be interpreted as different transcript levels (see
[29, 30, 49, 50]). For instance, the gag-based profiling
revealed approximately 53% of all sequences to be de-
rived from locus chr3q12.3_K-5. This locus together
with an additional three HML-2 loci comprised ap-
proximately 80% of all HML-2 transcripts detected.
Thus, only a small number of HML-2 loci predomin-
antly contribute to the HML-2 transcript pool in the
ALS and control tissue samples we examined. Simi-
larly, the bulk of LINE-1 mRNAs in cultured cells are
generated from a small subset of loci [79, 81].
Similarly, a high relative frequency of HML-2 transcripts
from locus chr3q12.3_K-5 was also observed for all exam-
ined samples when profiling was based on spliced rec/np9
or env amplicons. However, transcript levels for sequences
assignable to the Venter locus and to HERV-K111 were
more variable between samples, although overall similar
numbers of cDNA sequences had been examined per
sample. Very similar results were obtained previously
when investigating HML-2 locus origins of rec and np9
transcripts in 15 different human normal tissue types [17].
It is currently not clear whether those findings are due to
polymorphisms or to greatly variable transcript levels of
the HERV-K111 and the Venter loci in our samples. At
least 100 sequence variants of HERV-K111 have been re-
ported in human populations [82, 83]. It is conceivable
that among our samples several variants are transcribed
and that these sequence variants impede unambiguous as-
signment of cDNA sequences. It is furthermore not clear
why HERV-K111 transcripts were identified by np9(−like)
cDNA sequences but not by the gag-based profiling.
HERV-K111 was reported to be a full-length type 1 pro-
virus and our PCR primers should have been able to amp-
lify the HERV-K111 gag portion. It was also reported that
some HERV-K111 variants have 5′ deletions, including
portions of gag [83]. However, since these HERV-K111 5′
deletions were found in only a minority of the human
samples tested, their presence in all our samples seems
unlikely.
By mapping RNA-Seq reads to HML-2 loci, a recent
study identified HML-2 locus HERV-K(I) to be down-
regulated 1.09-fold, and loci c7_C and c10_A to be up-
regulated 1.13-fold and 1.11-fold, respectively, in ALS
versus control samples, though with inconclusive statis-
tical support [46]. Those locus designations correspond
to HML-2 loci chr3q21.2_K-4, chr7q34_K-15, and
chr10p14_K-16, respectively, in our study (for locus des-
ignations, see [50, 68, 69, 84]). Likewise, none of those
loci showed clear evidence of misregulation in our tran-
scription profilings, just as none of the other HML-2 loci
identified as transcribed in our study were consistently
altered in disease versus normal states. Our study there-
fore lends further support to transcription patterns of
HML-2 loci being very similar in the ALS versus the
control state. This finding might argue against the
disease-specific activation of particular, perhaps protein
encoding, HML-2 loci playing a causative, direct role in
the development of ALS. It is also conceivable that pre-
vious observations of differential HERV-K(HML-2) ex-
pression levels may relate to altered DNA global
methylation status and other epigenetic changes ob-
served in some ALS patients, which might in conse-
quence cause specific HERV-K(HML-2) loci to be
differentially transcribed [85–88]. It is furthermore
conceivable that differences in cellular composition of
brain tissues and cell types actually expressing
HERV-K(HML-2) affect analyses. Clearly, future studies
using single cell transcriptomics might help to clarify
this issue (see also below).
Disease-specific activation of HERV-K(HML-2) locus
transcription, as previously reported [42, 46], was
likewise not supported by our determination of
HERV-K(HML-2) transcript levels. HML-2 transcript
levels were also determined for an HML-2 gag region in
the study by Li et al. [46] and were found to be, on aver-
age, 3-fold higher in ALS compared to controls. Of fur-
ther note, Douville et al. [42] employed an amplicon
within the HML-2 pol gene and found approximately
2.5-fold higher HML-2 transcript levels in the occipital
cortex versus motor cortex, and greatly variable tran-
script levels in occipital cortex. Our gag-based study
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found HML-2 transcript levels approximately 4-fold
higher in motor cortex than occipital cortex and rather
limited variable transcript levels in the occipital region.
(As a side note, HERV-W transcript levels determined
by RT-qPCR were at least 10-fold higher than
HERV-K(HML-2) transcript levels when compared with
H9-hESCs and at similar levels in occipital and motor
cortex tissues.)
Notably, our results are consistent with a recent study
that failed to detect global differential expression of ei-
ther non-LTR or LTR retrotransposon subfamilies in
RNA-seq data of sALS vs control brain tissue samples
(although significant differences were seen between
C9orf72-mutant ALS vs sALS patients and controls)
[48]. The reasons for discrepancies between our study
and other published assessments (for example, ref. [46])
of differential transcription of HML-2 in ALS are un-
clear. While our sample size was relatively small, we
have been able to map transcribed HML-2 cDNA se-
quences with high confidence. Many HML-2 loci are
more or less different in sequence from each other and
some of them lack various proviral regions. Therefore,
PCR primer sets targeting different HML-2 proviral re-
gions in different RT-qPCR experiments might affect
measurements of overall HML-2 transcript levels due to
selective exclusion of some HML-2 loci. It is also con-
ceivable that using sets of multiple PCR primers care-
fully designed to compensate for HML-2 locus-specific
nucleotide differences in primer binding regions, as
employed in our study, as well as different RT-qPCR
conditions, contribute to overall different results. Fur-
ther refinement of a strategy specifically suited for iden-
tification of all transcribed HML-2 loci could yield more
conclusive results: information we present here could
prove useful in designing such strategies. A strategy cap-
able of determining transcript levels of each HML-2
locus as well as sense and antisense transcription of
transcribed HML-2 loci would clearly be favorable.
Locus-specific transcriptional activities of HML-2 in dif-
ferent cell types, especially in the ALS context, are cur-
rently little investigated (see also below).
The recent study by Li et al. [46] described experimen-
tal results in support of a contribution of HML-2 Env
protein in ALS. It is conceivable that isoforms other
than full-length Env protein were expressed from the
env gene-containing plasmid constructs used in experi-
ments of that study. Env gene transcripts of full-length
HML-2 constructs can be efficiently spliced to rec tran-
scripts unless splice donor or acceptor sites, and ideally
both, are mutated [36]. Since the RT-PCR primers
employed by Li et al. would not identify spliced rec tran-
scripts and the HERV-K(HML-2) Env antibody raised
against Env-TM sequence would not detect Rec protein
[46], it is conceivable that Rec protein was
(co-)expressed and itself may have affected cellular pro-
cesses. In this context, Boese et al. [19] found that cellu-
lar transformation by HML-2 Env was actually due to
Rec protein expressed from a lentiviral vector containing
full-length HML-2 env that had been spliced to rec in
the course of the experiment. It is furthermore conceiv-
able that full-length HML-2 Env protein expressed in ex-
periments by Li et al. [46] was processed by signal
peptidase to produce a stable Env-SP that may likewise
affect cellular processes [36]. An Env-SP would have
likewise escaped detection by an antibody directed
against HML-2 Env-TM.
We therefore suggest that proteins other than
full-length HML-2 Env should be taken into account
when considering a causative role of HML-2 in ALS
(although we also stress that our study does not provide
direct evidence for such an involvement). Our sugges-
tion is supported by our findings that HML-2 loci poten-
tially encoding full-length Env were transcribed only at
relatively low levels. Three type 2 loci with (near)
full-length Env ORFs (chr7p22.1_K-6, chr19q11_K-19,
chr11q22.1_K-25) had cDNA cloning frequencies be-
tween 0.2 and 1%. Very low levels of full-length HML-2
Env protein are further supported by our complete fail-
ure to detect any full-length HML-2 Env signal by
Western blotting of bulk brain or spinal cord tissue
lysates of ALS patients or controls, despite very strong
signal seen with 2102Ep whole cell lysates having the
same total protein concentration.
Similarly, type 1 loci 1q22_K-7 and chr22q11.21_K-24
potentially encoding “full-length” type 1-like Env pro-
tein, and type 1 locus chr1q23.3_K-18 potentially encod-
ing a similar protein truncated by 28 aa at its
C-terminus, were transcribed at relatively low levels in
our samples. Env protein variants from type 1 loci may
likewise undergo processing by furin to produce a TM
protein of approximately 27 kDa when unmodified, or
molecular masses of approximately 32–39 kDa due to
glycosylation [35]. Highest relative cDNA cloning fre-
quencies were observed, for example, for locus
chr3q12.3_K-5 (53%) potentially translating an internal
SU/OM product of approximately 27 kDa, and locus
chr19q13.12_K-29 (6.8%) potentially translating an
Env-SP/SU/OM product of 23 kDa. All of these protein
isoforms would be consistent with the approximately
27 kDa bands detected in our Western blot experiments
in a subset of spinal cord and especially cerebellum sam-
ples (RT-qPCR results confirmed highest HML-2 env
transcript levels in cerebellum samples). However, the
HERM-1811-5 antibody is directed against HML-2
Env-TM [72, 73, 75, 78]. HML-2 SU/OM and Env-SP/
SU/OM proteins thus would remain undetected by this
antibody. Our Western blot results therefore suggest
that the approximately 27 kDa protein detected in a
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subset of samples represents Env-TM produced from ei-
ther an HML-2 type 1 or type 2 env gene that furthermore
seemed to remain unglycosylated. We failed, however, to
associate increased expression of truncated Env protein
products with ALS versus control tissue samples.
Rec protein may also be expressed in the ALS context.
HML-2 type 2 loci chr3q21.2_K-4 and, to much lesser
degree, chr7p22.1_K-6 and chr10p14_K-16 potentially
encode Rec proteins. Locus chr3q21.2_K-4 may also
generate a Rec-like protein by alternative splicing, short-
ened by 17 aa and lacking a previously reported TZFP/
PLZF binding domain [19, 20, 24]. It is currently not
clear how much such aa differences in predicted Rec
proteins might alter previously demonstrated protein in-
teractions and biological activities of the Rec variants
(see ref. [12], and references therein).
Our analysis also identified several HML-2 loci poten-
tially encoding the Np9 protein. Locus chr3q12.3_K-5 was
cloned at high relative levels (~ 53%) in the gag-based pro-
filing, and further corroborated by profiling results
from the rec/np9 and env gene 5′ regions. In light of
the previously reported short half-life of Np9 [18],
the actual amount of Np9 protein in ALS tissue could
be difficult to determine. We note that a transcribed
HML-2 locus in human chromosome 22q11.23, not
detected as transcribed by our profiling strategy be-
cause of mismatches in primer binding sites, poten-
tially encodes an Np9-like protein [29]. It is currently
unknown whether this particular locus is also tran-
scribed in the ALS context and whether it should be
considered in future studies concerned with HML-2
coding capacity in the ALS context.
Another HML-2 Env protein variant may also have to
be considered in the ALS context. We identified in a
number of ALS and normal samples relatively high
levels of np9-like spliced transcript likely originating
from the Venter locus and HERV-K111. The predicted
protein consists of Env and Rec portions at the
N-terminus and an Env portion at the C-terminus. Be-
sides a TZFP-interacting domain in the Env/Rec
N-terminal portion, we note that the C-terminal Env
portion essentially comprises the cytoplasmic tail of
Env-TM that was recently described to be required for
activation of the ERK1/2 pathway, including phosphoryl-
ation of ERK1/2 and activation of transcription factors
EGR1, ETV4 and ETV5 [31]. The biological relevance
for ALS of protein potentially encoded by the Venter
locus and HERVK-111 is unknown.
Our study provides potentially valuable insights and
hints for future directions in the study of potential
HERV-K(HML-2) effects on neurological and neurode-
generative disease. The study also calls for larger scale
transcription and proteomic profiling of HML-2 loci in
the ALS context in order to better comprehend potential
roles of HML-2. Sanger-based DNA sequencing may
have advantages over short-read RNA-Seq analyses,
which can be confounded by the relatively high sequence
similarity of biologically relevant, coding competent
HML-2 loci. However, specifically designed strategies for
describing HML-2 transcription using high-quality
long-read RNA-Seq data would clearly be advantageous
considering the much higher amount of sequence infor-
mation generated compared to Sanger sequencing. Pre-
sumably, an optimized RNA-Seq based strategy could
also provide much more accurate information on
HML-2 locus-specific transcript levels than RT-qPCR
alone. On the other side, RNA-Seq requires RNA of
higher quality compared to RT-qPCR. Many ALS and
control tissue samples may not be suited for RNA-Seq
analysis because of too long post-mortem intervals and
thus a higher level of RNA degradation. RNA quality may
thus pose a main limitation when studying HML-2 ex-
pression in the ALS context by RNA-seq. A number of
RNA samples in our study had lower RIN values, yet those
lower quality RNAs did not significantly affect our results.
Instead of RNA-Seq, RT-PCR-based high-throughput
amplicon sequencing may be best suited for samples with
lower RNA quality.
We further note that possibly a relatively minor propor-
tion of cells in tissue samples from ALS patients may ex-
press HML-2 Env protein. In the study of Li et al. [46]
only about 20% of cells stained positive by immunofluor-
escence in frontal cortex and lumbar spinal cord tissue
sections when using an Env-TM antibody (and our data
suggest it is likely little of that signal derived from the de-
tection of full-length Env protein). The presence of mixed
cell type populations in bulk tissue samples could also
have an influence on measurements of HML-2 transcript
levels: perhaps greater cell type diversity explains the often
higher and overall much more variable HML-2 transcript
levels we detected in cerebellum versus other tissue types.
RNA amplification of bulk tissues may not be the best
strategy for determining HML-2 transcript levels in the
ALS context. Dilution effects when examining bulk tissues
may yield an incomplete depiction of transcribed HML-2
loci and their relative transcript levels in potentially clinic-
ally relevant cell types if not sufficiently compensated by a
higher number of cDNA sequence reads.
We have been unable to control in our analyses for
the selective loss of motor neurons that would be ex-
pected to occur in tissues of ALS patients. We note
that this is also a potential problem of other studies
in this area [42, 46, 48]. Lack of normalization to
neuronal loss may currently represent a limitation
when studying HML-2 expression in the ALS context.
If motor neurons contribute a significant percentage
of the HML-2 transcripts in a bulk tissue sample
(as suggested in ref. [46]), loss of neurons would
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reduce apparent overall HML-2 transcript levels in
ALS versus control samples. On the other hand,
non-neuronal cell types may also contribute HML-2
transcripts at variable levels. Therefore, presorting of
bulk neuronal tissues for specific neuronal cell types
is one strategy for overcoming this potential bias.
Ideally, high-throughput HML-2-specific transcription
profiling of single cells sorted by flow cytometry for
positive staining with HML-2 Env protein would be
useful for identifying HML-2 loci of potential rele-
vance, including the actual HML-2 Env(−like) protein
isoforms potentially affecting cellular processes. Such
an analysis could be complemented by identification
of HML-2 (Env) protein forms actually expressed in
respective cell types by immunoprecipitation using
isoform-specific antibodies followed by proteomic
identification of their sequences.
Conclusions
HERV-K(HML-2) and HML-2-encoded Envelope pro-
tein has recently been implicated in the development
of ALS. Our study provides further insight into the
relevance of HML-2 for ALS. We found similar tran-
scriptional activities of specific HML-2 loci as well as
statistically indifferent overall HML-2 transcript levels
in ALS-derived and control bulk tissue samples, argu-
ing against higher transcriptional activity of one or
several HML-2 loci in ALS-derived tissue. Full-length
Envelope protein was undetectable in protein lysates
from ALS and control bulk tissue samples; smaller
Env isoforms were seen although these did not obvi-
ously favor the disease. Our findings suggest that
various HML-2-encoded proteins, some of them
known to affect cell biology, may be expressed in
ALS and control states in the central nervous system
tissue types investigated in our study and thus may
require further specific investigations. Our study fur-
thermore calls for high-throughput strategies specific-
ally suited for a comprehensive description of HML-2
transcription in order to better comprehend the role
of HML-2 in ALS and potentially other neurodegen-
erative diseases. Such increased understanding is of
special significance as the U.S. National Institutes of
Health engages in a Phase I clinical trial investigating
HERV-K(HML-2) suppression using antiretroviral
therapy in volunteers with ALS (ClinicalTrials.gov
Identifier: NCT02437110).
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